Dabigatranate, or dabigatran capsule, does not treat dizziness and is an anticoagulant that is mainly used in the treatment of thrombotic disorders. Dabigatranate capsules belong to the direct thrombin inhibitors, can prolong the clotting time, clinically used mainly for non-valvular disease atrial fibrillation pre-treatment, seek to reduce the patient’s risk of stroke and systemic arterial embolism. Dizziness patients may have cerebral arterial blood supply insufficiency or inner ear disease, atherosclerosis is the main cause of morbidity, in the arteriosclerosis on the basis of blood supply insufficiency, need to be given to improve the cerebral blood supply of medication, dabigatran does not have to improve the role of the cerebral blood supply, dizziness does not have a significant effect. Dabigatran capsule belongs to the western prescription drugs, the main adverse reaction of the drug is bleeding, such as bleeding of the skin and mucous membranes, serious gastrointestinal and intracranial hemorrhage can occur, allergic to the drug components, patients with short-term surgery, patients with severe hepatic insufficiency, active bleeding, mechanical valvulopathy is prohibited. Patients with dizziness should clarify the cause of the disease in time, and give treatment under the guidance of the doctor, can not take oral dabigatran etexilate capsule for treatment.